# Ellagic acid is associated with reduced pancreatic carcinogenesis and modulation of the IL-6/STAT3 pathway

**Authors:** Hiroyuki Kato, Aya Naiki-Ito, Masayuki Komura, Yuko Nagayasu, Motonori Sato, Xiaochen Kuang, Aya Nagano, Satoru Takahashi

PMC · DOI: 10.1186/s41021-026-00353-3 · 2026-03-02

## TL;DR

Ellagic acid may help prevent pancreatic cancer by reducing tumor development and affecting the IL-6/STAT3 pathway in a hamster model.

## Contribution

This study demonstrates EA's chemopreventive potential in PDAC and identifies the IL-6/STAT3 pathway as a key target.

## Key findings

- EA reduced PDAC incidence and multiplicity in a hamster model.
- EA treatment led to lower pSTAT3 expression and reduced cell proliferation and invasion.
- The Res/STAT3 pathway showed minimal involvement in EA's effects.

## Abstract

The 5-year survival of pancreatic ductal adenocarcinoma (PDAC) remains about 10% despite therapeutic advances, underscoring the need for effective preventive and early intervention strategies. Ellagic acid (EA), a naturally occurring polyphenol, has been associated with demonstrated antitumor activity in several malignancies. However, its potential role in preventing PDAC development remains unclear. In this study, we examined the chemopreventive potential and underlying mechanisms of EA in a hamster model of PDAC induced by a high-fat diet and N-nitrosobis(2-oxopropyl)amine.

Dietary EA (0.1% w/w) was associated with significantly reduction in both the incidence and multiplicity of PDACs compared to controls. The proportion of histologically normal pancreatic ducts increased and the Ki-67 labeling index decreased in pancreatic intraepithelial neoplasia (PanIN) following EA exposure. In vitro, cell proliferation decreased in a dose-dependent manner, G1 arrest was induced, and invasion was diminished after EA treatment. Multiplex Western blotting revealed lower inhibition of the IL-6/STAT3 pathway. The proportion of pSTAT3-positive cells in hamster PanINs and PDACs was significantly lower in the EA-treated groups than in controls. Because a high-fat diet is known to elevate adipocytokines, and resistin (Res) has been implicated in STAT3 regulation, the Res/STAT3 axis was also examined. Res-associated promotion of invasion was observed but there was no proliferation in vitro, and pSTAT3 expression did not increase. Similarly, serum Res levels did not differ significantly across groups, suggesting a limited contribution of the Res/STAT3 pathway in this hamster model.

EA treatment was associated with reduced pancreatic carcinogenesis in vivo. The IL-6/STAT3 pathway appears to be a primary molecular target under our experimental conditions, whereas the contribution of Res is likely minimal. These findings support the potential of EA as a preventive agent against pancreatic cancer.

The online version contains supplementary material available at 10.1186/s41021-026-00353-3.

## Linked entities

- **Proteins:** IL6 (interleukin 6), STAT3 (signal transducer and activator of transcription 3), Res (Resurrector)
- **Chemicals:** Ellagic acid (PubChem CID 5281855), N-nitrosobis(2-oxopropyl)amine (PubChem CID 43371)
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184), pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, CST12P (cystatin 12, pseudogene) [NCBI Gene 106478911] {aka Cst, Ctes4, E2}, SHH (sonic hedgehog signaling molecule) [NCBI Gene 6469] {aka HHG1, HLP3, HPE3, MCOPCB5, SMMCI, ShhNC}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CAP1 (cyclase associated actin cytoskeleton regulatory protein 1) [NCBI Gene 10487] {aka CAP, CAP1-PEN}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** insulin resistance (MESH:D007333), prostate, colorectal, and lung cancers (MESH:D015179), prostate disorders (MESH:D011472), biliary cysts (MESH:D003560), biliary hyperplasia (MESH:D006965), colon, prostate, liver, lung, oral, breast, urinary bladder, and ovarian cancers (MESH:D010051), Type 2 diabetes (MESH:D003924), BilIN (MESH:D002578), esophageal squamous cell carcinoma (MESH:D000077277), Pulmonary tumors (MESH:D009369), diabetes (MESH:D003920), nonalcoholic fatty liver disease (MESH:D065626), pancreatic cancer (MESH:D010190), cervical cancer (MESH:D002583), hepatocellular adenoma (MESH:D018248), melanoma (MESH:D008545), prostate cancer (MESH:D011471), inflammation (MESH:D007249), PDAC (MESH:D021441), cholangioma (MESH:D002759), pancreatic carcinogenesis (MESH:D063646), cholangiocarcinoma (MESH:D018281)
- **Chemicals:** Ser (MESH:D012694), N-nitroso-bis(2-oxopropyl)-amine (MESH:C013622), hematoxylin (MESH:D006416), H&amp;E (MESH:D006371), propidium iodide (MESH:D011419), 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2 H-5-tetrazolio]-1,3-benzene (-), DMSO (MESH:D004121), formalin (MESH:D005557), DAB (MESH:C000469), EA (MESH:D004610), PBS (MESH:D007854), eosin (MESH:D004801), CO2 (MESH:D002245), polyphenol (MESH:D059808), toluidine (MESH:D014052), EDTA (MESH:D004492), oxygen (MESH:D010100), paraffin (MESH:D010232), fat (MESH:D005223), acrylamide (MESH:D020106), SDS (MESH:D012967), isoflurane (MESH:D007530), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cricetinae (hamsters, subfamily) [taxon 10026], Mesocricetus auratus (golden hamster, species) [taxon 10036], Cricetus cricetus (black-bellied hamster, species) [taxon 10034], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** PANC1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), MIAPaCa2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428), HPD1NR — Mesocricetus auratus (Golden hamster), Hamster pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_2072)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964673/full.md

---
Source: https://tomesphere.com/paper/PMC12964673